The National Institute for Health and Clinical Excellence (NICE) British Watchdog, recommended use of Sanofi-Aventis drug, Multaq (Donedarone) indicated for patients with atrial fibrillation and to be reimbursed by the National Health Service.

The National Institute for Health and Clinical Excellence (NICE) British watchdog, gave negative recommendation for the National Health Service (NHS) reimbursement of Takeda Pharmaceutical Co. bone cancer drug, Mepact (Mifamurtide). NICE considered the drug has limited effectiveness and high cost.

The National Institute for Health and Clinical Excellence (NICE), British Watchdog, rejected reimbursement by The National Health Service for Roche Holding AG drug, Avastin (Bevacizumab) indicated to treat advanced breast cancer.

Allergan Inc. announced that The Medicines and Healthcare Products Regulatory Agency –MHRA- cleared Botox (Botulinum Toxin Type A) to be used for migraine treatment.

The National Institute for Health and Clinical Excellence (NICE), the British watchdog that evaluates cost-benefit of drugs to be reimbursed by the National Health Institute, rejected use of Roche Holding AG blockbuster drug, Herceptin (Trastuzumab) in patients with stomach cancer.

British watchdog, the National Institute for Health and Clinical Excellence (NICE), rejects reimbursement by the National Health Service (NHS) of Novartis AG, Afinitor (Everolimus) drug, indicated for the second line treatment of advanced renal cell carcinoma.

British watchdog, the National Institute for Health and Clinical Excellence (NICE) recommended use of Roche Holding AG, RoActemra (Tocilimumab), to be reimbursed by the National Health Service (NHS) indicated to treat severe rheumatoid arthritis.

The National Institute for Health and Clinical Excellence (NICE) which decides whether drugs should be paid for on the state-funded National Health Service, decided to give a negative recommendation on Novartis AG, blockbuster drug, Glivec (Imatinib) for the treatment of surgery removed gastrointestinal stromal tumours.

The National Institute for Health and Clinical Excellence, British watchdog said it could not recommend Arzerra (Ofatumumab)drug for reimbursement on the National Health Service (NHS) because evidence did not yet show how well it works compared with standard treatment. The drug is indicated to treat chronic lymphocytic leukemia and developed by Genmab A/S and GlaxoSmithKline Plc.

The National Institute for Health and Clinical Excellence (NICE), the U.K. agency that advises the state-run National Health Service on cost-effective treatments, recommended use of oral drug Novo Nordisk A/S, Victoza (Liraglutide) in patients with diabetes type 2.

GlaxoSmithKline Plc., breast cáncer drug, Tyverb/Tykerb (Lapatinib), was rejected again by the National Institute for Health and Clinical Excellence (NICE), british watchdog that evaluates benefit-cost of drugs for the National Health Service (NHS) by saying that the cancer oral drug to treat breast cancer with over-express of a protein called HER2, offers limited benefit and high price.

According to the National Institute for Clinical Excellence (NICE) British watchdog for the National Health Service, Novartis asthma drug Xolair (Omalizumab) will not be recommended as it is too expensive.

The National Institute for Health and Clinical Excellence (NICE), the a U.K. agency that advises the state-run National Health Service on cost-effective treatments, does not recommend use of Nexavar (Sorafenib), a Bayer AG and Onyx Pharmaceuticals Inc. drug, indicated to treat hepatocellular carcinoma.

The consumer defense group Public Citizen formally requested that the Food and Drug Administration stop review of Eli Lilly and Daiichi Sankyo Co blood thinner drug Effient (Prasugrel) stating a presumed risk of the tested dose for the presentation study.

The EU Commission of Trade will take more than a month to analyze the proposed Pfizer takeover of Wyeth, the most important drug maker´s merger of the decade. The deal is valued around 68 billion dollars and will make the biggest pharmaceutical company of the trade.

GlaxoSmithKline Plc. obtained by the Federal Trade Commission, formal permission to acquire privately owned skincare company Stiefel Labs. Inc. The deal was proposed April 20th. last year in more than 3.500 million dollars.

Roche Holding AG cut the price of its Tarceva lung-cancer drug for the U.K.’s National Health Service, gaining the recommendation of the National Institute for Health and Clinical Excellence (NICE), a government agency that advises on the cost-effectiveness of medicines.

The number of serious drug reactions and deaths reported to the U.S. government shot up in the first three months of this year to set a new record, the health industry watchdog Institute for Safe Medication Practices reported – nearly 21,000 serious drug reactions, more than 4,800 deaths according to the Food and Drug Administration data. Heparin and Chantix/Champix lead the list. Further details.

The U.S. Department of Health and Human Services updated its HIV treatment guidelines, placing Gilead´s Truvada (a combination of Emtriva and Viread) as preferred regimen. GlaxoSmithKline´s Epzicom is listed as alternative. Further details.